Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-07-15
1996-12-31
LeGuyader, John L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530351, 530380, 530829, 530830, 424484, 424 851, A61K 3818, A61K 3516, C07K 1449, C07K 130
Patent
active
055894623
DESCRIPTION:
BRIEF SUMMARY
The subject of the invention is the production of a biological adhesive containing coagulable human plasma proteins. The biological adhesive obtained according to the invention contains especially growth factors of platelet origin.
It is known that concentrates of thrombin-coagulable proteins, or fibrinogen solutions, are used in the production of an adhesive material which makes it possible especially to join living tissues while exerting a haemostatic action; see for example Patent FR-2,448,900. This adhesive material is commonly called "biological adhesive" and is used in surgery.
Biological adhesives make it possible to reproduce, under physiological conditions, the final phase of the coagulation process. For that, a solution containing fibrinogen and factor XIII are mixed, immediately before use, with a solution containing thrombin and calcium ions on living tissue to be treated. Fibrinogen, in the presence of thrombin and calcium ions, is converted to fibrin. The fibrin monomers join together to form fibrin polymers and these polymers are cross-linked by the action of activated factor XIII. Factor XIII, activated under the action of thrombin in the presence of calcium ions, is a transamidase which forms peptide bonds between the fibrin chains with formation of a network.
In the present application, the name "biological adhesive" will refer to a concentrate of thrombin-coagulable proteins, although in fact it is only in the presence of thrombin and calcium salts (or after activation of the prothrombin which it contains) that such a concentrate truly constitutes an adhesive.
The formation of the network of fibrin is responsible for the haemostatic activity of the biological adhesive. Moreover, fibrin adheres to the surrounding tissues, especially through fibronectin and collagen. In addition, activated factor XIII forms peptide bonds fibrin and fibronectin, thereby reinforcing the adhesive properties.
It is known that fibrin clot disappears gradually, in vivo, under the action of a proteolytic enzyme called plasmin, thereby limiting the duration of the adhesive bonding. It is however possible to reinforce the duration of action of biological adhesives by supplementing them for example with alpha-2-antiplasmin or a protease inhibitor such as aprotinin, or alternatively epsilon-aminocaproic acid.
The applications of biological adhesives are numerous, in particular in surgery for avoiding bleeding, for replacing suture threads or for reinforcing sutures.
However, biological adhesives do not have a specific activity capable of promoting cicatrization.
It is known that cicatrization is promoted especially by certain growth factors acting directly on target cells present in the wound. These growth factors induce multiplication or differentiation, or even cell attraction (chemotactism). Blood platelets (or thrombocytes) are one of the principal sources of growth factors in blood.
During a cellular lesion in vivo, the thrombocytes liberate the growth factors contained in granules, under the action of thrombocyte activators, including thrombin. The supernatants of activated platelets contain a great diversity of molecules, such as for example platelet-derived growth factor or PDGF, transforming growth factor beta, basic fibroblast growth factor, platelet factor 4, platelet-derived endothelial growth factor, heparin-binding epidermal growth factor, insulin-like growth factor 1, connective-tissue activating peptide III, beta-thromboglobulin, epidermal growth factor, plasminogen, Von Willebrand factor, fibrinogen, serotonin, histamine, adenosine di- and triphosphate, fibronectin, vitronectin, platelet factor XIII, proteolytic or glycolytic enzymes, metabolites of arachidonic acid and the like; see especially H. L. Wong & S. M. Wahl, in "Peptide Growth Factors and their Receptors" Sporn & Roberts Eds., Springer-Verlag. Berlin, p. 510; R. A. Terkeltaub & M. H. Ginsberg, in "The Molecular and Cellular Biology of Wound repair", Clark & Henson Eds., Plenum Press, New York, p. 38.
Platelets extracts contain a high mitog
REFERENCES:
patent: 4167823 (1979-09-01), Kumming
patent: 4427650 (1984-01-01), Stroetmann
patent: 4427651 (1984-01-01), Stroetmann
patent: 4442655 (1984-04-01), Stroetmann
patent: 4627879 (1986-12-01), Rose et al.
patent: 4760131 (1988-07-01), Sundsmo et al.
patent: 4963657 (1990-10-01), Pixley
patent: 5030215 (1991-07-01), Morse et al.
patent: 5185001 (1993-02-01), Galanakis
patent: 5219328 (1993-06-01), Morse et al.
patent: 5260420 (1993-11-01), Burnouf-Radosevloh et al.
patent: 5318782 (1994-06-01), Weis-Fogh
Deuel et al. "Human Platelet-Derived Growth Factor" J. Biol. Chem. 256(17) 8896-8899, 1981.
Ochsner et al. "Fibrin Glue as a Hemostatic Agent in Hepatic & Splenic Trauma" J. Trauma 30(7):884-887, 1990.
Delmas Olivier
Patat Jean-Louis
Schmitthaeusler Roland
Degen Nancy J.
Inoteb
LeGuyader John L.
LandOfFree
Method of preparing a biological adhesive enriched with platelet does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of preparing a biological adhesive enriched with platelet, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of preparing a biological adhesive enriched with platelet will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1142162